A Study of LY3405105 in Participants With Advanced Cancer

Phase 1 Terminated 54 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts phase 1a and phase 1b. Participants will only enroll in one part.

Timeline

Start: 2019-01-31
Primary completion: 2021-02-04
Completion: 2021-02-04

Outcome

Outcome not reported

Stopped: “The study was terminated for lack of sufficient efficacy.”

Publications

Garralda E, Schram AM, Bedard PL, Schwartz GK, Yuen E, McNeely SC, Ribeiro S, Cunningham J, Wang Y, Urunuela A, Xu X, LoRusso P. A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors. Oncologist. 2024 Jan 5;29(1):e131-e140. doi: 10.1093/oncolo/oyad215.
Sava GP, Fan H, Coombes RC, Buluwela L, Ali S. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. doi: 10.1007/s10555-020-09885-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3405105	Unknown	1 mg	Oral
Subject	LY3405105	Unknown	2 mg	Oral
Subject	LY3405105	Unknown	20 mg	Oral
Subject	LY3405105	Unknown	25 mg	Oral
Subject	LY3405105	Unknown	35 mg	Oral
Subject	LY3405105	Unknown	45 mg	Oral